Improving Perioperative Outcomes in Gastrointestinal Cancer – Personal Highlights

Neoadjuvant therapies have the potential to increase R0 resectability and thereby improving surgical outcomes. Two recent phase II trials, PANDAS/PRODIGE 44 (1) and NICHE-2 (2), investigated neoadjuvant treatment approaches for borderline resectable pancreatic cancer and locally advanced mismatch-repair deficient (dMMR) colon cancer, respectively, with notable implications for clinical practice.